Article
Dr. Jack Cush Reviews the news and journal reports on CVA, TKA, PJP, ADA, and more!
All News
Article
Cerebrovascular ischemic events (CIE) can be one of the most severe complications of giant cell arteritis (GCA), but is seen in 4-5% of GCA patients according to a recent French University Hospital.
Article
The hallmark of systemic sclerosis is scleroderma, but less than 10% of SSc patients have sine scleroderma (ssSSc). A EUSTAR database review compared the manifestations and outcomes of ssSSC to limited cutaneous SSc and diffuse cutaneous SSc.
Article
A large, retrospective, multinational study of patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) shows they may be at risk for cardiovascular events (CVEs).
Article
During nintedanib treatment for interstitial lung disease associated with systemic sclerosis (SSc-ILD), clinicians prescribing the drug should be watchful for an unusual, indirect side effect, trial data suggested.
Dr. John Cush
Tweet
Hong Kong study shows Very low dose prednisolone (<5 mg/d) doesn't confer excessive CV risk.
2 233 RA pts (105 826 Pt-years FUV; mean duration 8.7 yrs) - 7% developed MACE. MACE risk incr 7% per month in those taking ≥5 mg pred. https://t.co/lcehOgaqCQ https://t.co/AhWGnUuYcc
Dr. John Cush
Tweet
High mortality risk predictors in patients with anti-MDA5 dermatomyositis include:
- rapidly progressive interstitial lung disease
- anti-Ro52 antibody
- age > 57 years
(based on study of 126 MDA-5+ DM pts)
https://t.co/VCyLhStFgX https://t.co/y3CyzOlwDt
Dr. John Cush
Tweet
Study of Veterans, Medicare, Medicaid RA pts (73070) pts, matched 1:10 w/ non-RA (639268) looked ataortic valve risk; RA pts have incr risk incident AS (adj HR 1.48), aortic valve surgery (aHR 1.34) & AS-related death (aHR 1.26). AS incidence=3.97/1000PYs https://t.co/rvA59hn6FE https://t.co/IS9jjuhYWv
Dr. John Cush
Tweet
Estimated 795 000 Americans are misdiagnosed annually (371,000 pts die; 424,000 permanently disabled). Just 15 diseases account for about half of all serious harms & top 5 (Stroke, Sepsis, Pneumonia, VTE, Lung CA) account for 39% https://t.co/3pvgGLLHbs https://t.co/94ij9txIyK
Dr. John Cush
Tweet
Study of >19K RA pts in National Databank showed that Opioids vs NSAID use had similar MACE risk(20.6 vs 18.9/1000 PY), but opioids had higher mortality (13.5 vs 10.8/1000 PY; HR1.33) & VTE risk(HR=1.41). Opioids are not safer than NSAIDs https://t.co/J56BqYMKM1 https://t.co/xiz4GGUnJC
Dr. John Cush
Tweet
GCA and the Risk of Cerebrovascular Ischemic Events
Cerebrovascular ischemic events (CIE) can be one of the most severe complications of giant cell arteritis (GCA), but is seen in 4-5% of GCA patients according to a recent French University Hospital.
https://t.co/MAjgWg71vK https://t.co/UhMtiWf7gh
Dr. John Cush
Tweet
Full read review of clinical trials in CTD-ILD, specifically looking at:
- Frequency of ILD in RA, SLE, SSc, Sjogr, PM/DM & Rx outcomes
- Results w/ RTX, MMF, CYC, IL-6i, nintedinib, pirfenidone, Stem cell transplant
https://t.co/gUOV3IWt4P https://t.co/WM1HvTmNCq
Dr. John Cush
Tweet
Check SSc-ILD Patients on Nintedinib for Malnutrition
During nintedanib treatment for interstitial lung disease associated with SSc-ILD, clinicians prescribing the drug should be watchful for an unusual, indirect side effect, trial data suggested.
https://t.co/TmN71qSCb2 https://t.co/TVU2qcPdZE
Dr. John Cush
Tweet
Predictors of Cardiovascular Events in ANCA-Associated Vasculitis
A large, retrospective, multinational study of patients with ANCA-AAV shows they may be at risk for CVEs.
https://t.co/k9XPolEXKc https://t.co/0nxai3Eqe2
Dr. John Cush
Tweet
Check SSc-ILD Patients on Nintedinib for Malnutrition
During nintedanib treatment for interstitial lung disease associated with SSc-ILD, clinicians prescribing the drug should be watchful for an unusual, indirect side effect, trial data suggested.
https://t.co/5Q3xCwLvPa https://t.co/mGD3DCYZR0
Dr. John Cush
Tweet
JAKi in Rheumatoid Arthritis: Cancer and Cardiovascular Risks
Dr. Antoni Chan discusses abstracts OP0132, POS0831, and OP0133 presented at EULAR 2023 in Milan, Italy.
https://t.co/ApLaPf7uKP https://t.co/nbZgwIlHyb
Dr. John Cush
Tweet
Among 247.3 million US adults. 10.0% (20.3 million) had CVD & 56% were at risk for CVD. Yet only 3.6 million CVD (18%) & 34.5 million at risk for CVD (26%) used wearable devices (compared to 29% in US adults, but less than half wear every day. https://t.co/04xqtkw61x https://t.co/ETTjamvHi2
Dr. John Cush
Tweet
CV and Cancer Risk with JAK inhibitors
Dr. Jonathan Kay discusses abstract OP0132 presented at EULAR 2023 in Milan, Italy.
https://t.co/SZLohnNEa1 https://t.co/ZEv0Q2NSBf
Dr. John Cush
Tweet
Watch: SpA and Interstitial Lung Disease
Dr. Eric Ruderman discusses abstract OP0006 presented at EULAR 2023 in Milan, Italy.
https://t.co/wsR3gv1jSr https://t.co/ULYbJeoFHi
Dr. John Cush
Tweet
An update on JAK inhibitors and cardiovascular risks
Dr. Antoni Chan ( @synovialjoints ) shares #EULAR23 developments on JAK/TYK2 inhibitors.
https://t.co/VovWE2OuXW https://t.co/QXKZLh5RuK
